Supportive of this postulate is a similar rate of an absence of locus-specific LOH in BRCA2 carriers in the two independent tumor sets, similar HRD-Mean scores to nonBRCA tumors and higher percentage of aging signature in those tumors without BRCA locus-specific LOH in the Penn data set. This evidence concerns the gene BRCA2 and neoplasm.